RTTR Insider Trading Activity and SEC Form 4 Filings
RTTR insider trading summary
No open-market insider purchases or sales of Ritter Pharmaceuticals Inc (RTTR) have been reported on SEC Form 4 in the past 12 months.
Latest RTTR insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 12, 2020 | Noah Doyle | Director | Sell | $110K (500,000 @ $0.22) |
| Mar 4, 2020 | Ira E. Ritter | Cob, CSO | Sell | $7K (18,750 @ $0.38) |
| Mar 4, 2020 | Andrew J Ritter | CEO and President | Sell | $7K (18,750 @ $0.38) |
| Aug 17, 2018 | Matthew W Foehr | Director | Buy | $40K (19,751 @ $2.04) |
| Oct 3, 2017 | Noah Doyle | Director | Buy | $0 (5,000,000 @ $0.00) |
| Oct 3, 2017 | Ira E. Ritter | Exec. Chairman, CSO | Buy | $0 (187,500 @ $0.00) |
| Oct 3, 2017 | Javelin Venture Partners, L.P. | 10% Owner | Buy | $0 (5,000,000 @ $0.00) |
| Oct 3, 2017 | Andrew J Ritter | President | Buy | $0 (187,500 @ $0.00) |
| May 18, 2017 | Matthew W Foehr | Director | Buy | $11K (18,000 @ $0.62) |
| May 11, 2017 | Michael D Step | CEO | Buy | $8K (13,000 @ $0.62) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.